The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera

European Journal of Haematology

Volumn 86, Issue 2, 2011, Pages 148-155

  Abdulkarim, Khadija ^a   Ridell, Börje ^a   Johansson, Peter ^a,b   Kutti, Jack ^a   Safai Kutti, Soodabeh ^a   Andréasson, Björn ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NU Hospital Organization   (Sweden)

Author keywords

Acute leukemia; Bone marrow cellularity; Essential thrombocythemia; Myelofibrosis; Polycythemia vera; Reticulin

Indexed keywords

HEMOGLOBIN; RETICULIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD; BONE MARROW; BONE MARROW BIOPSY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELOFIBROSIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROBABILITY; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS;

AGED; BIOPSY; BONE MARROW; BONE MARROW CELLS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYCYTHEMIA VERA; PROGNOSIS; RETICULIN; THROMBOCYTHEMIA, ESSENTIAL; TIME FACTORS;

EID: 78651456842     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01548.x     Document Type: Article

References (44)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Eng J Med 2005; 352:1779-90.
4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
6. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-53.
7. Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008;111:3383-7.
8. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-61.
9. Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N, et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007;21:2074-5.
10. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21:1952-9.
11. Thiele J, Kvasnicka HM. Myelofibrosis in chronic myeloproliferative disorders - dynamics and clinical impact. Histol Histopathol 2006;21:1367-78.
12. Abdulkarim K, Girodon F, Johansson P, Maynadie M, Kutti J, Carli PM, et al. AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol 2009;82:106-11.
13. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J 2003;4:198-207.
14. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159-66.
15. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;13:339-51.
16. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 1975;12:409-32.
17. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986;23:177-82.
18. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-43.
19. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.
20. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
21. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008;111:60-70.
22. Kvasnicka HM, Thiele J. Classification of Ph-negative chronic myeloproliferative disorders - morphology as the yardstick of classification. Pathobiology 2007;74:63-71.
23. Johansson P, Kutti J, Andreasson B, Safai-Kutti S, Vilen L, Wedel H, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J Intern Med 2004;256:161-5.
24. Ridell B, Carneskog J, Wedel H, Vilen L, Hogh Dufva I, Mellqvist UH, et al. Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweden 1983-1992. Eur J Haematol 2000;65:267-71.
25. Revesz P, Carneskog J, Wadenvik H, Jarneborn L, Kutti J. Measurement of spleen size using gamma camera scintigraphy in essential thrombocythaemia. Eur J Haematol 1993;51:141-3.
26. Carneskog J, Wadenvik H, Fjalling M, Kutti J. Assessment of spleen size using gamma camera scintigraphy in newly diagnosed patients with essential thrombocythaemia and polycythaemia vera. Eur J Haematol 1996;56:158-62.
27. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie, Virginina. Ann Oncol 1999;10:1419-32.
28. Bancroft JD, Stevens A. Theory and Practice of Histological Techniques. Edinburgh, London, Melbourne and New York: Churchill Livingstone, 1990.
29. Burston J, Pinniger JL. The reticulin content of bone marrow in haematological disorders. Br J Haematol 1963;9:172-84.
30. Dahlberg G. Statistical Methods for Medical and Biological Students. London: George Allen &Unwin, 1948.
31. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-63.
32. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 1995;123:656-64.
33. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999;61:10-5.
34. Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 2004;89:1306-13.
35. Alvarez-Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez-Boluda JC, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007;21:1218-23.
36. Phekoo KJ, Richards MA, Moller H, Schey SA. The incidence and outcome of myeloid malignancies in 2, 112 adult patients in southeast England. Haematologica 2006;91:1400-4.
37. Bai J, Xue Y, Ye L, Yao J, Zhou C, Shao Z, et al. Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China. Int J Hematol 2008;88:530-5.
38. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008;93:1645-51.
39. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008.
40. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008;22:905-14.
41. Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL, et al. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol 2008;80:386-90.
42. Girodon F, Dutrillaux F, Broseus J, Mounier M, Goussot V, Bardonnaud P, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia 2010;24:900-3.
43. Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009;115:5740-5.
44. Caramazza D, Caracciolo C, Barone R, Malato A, Saccullo G, Cigna V, et al. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol 2009;88:967-71.